Turning Point Therapeutics Inc TPTX:NASDAQ

Last Price$75.40NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change+0.40(0.53%)
Bid (Size)$75.41 (3)
Ask (Size)$75.42 (1)
Day Low / High$74.92 - 75.69
Volume1.7 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/12/2022


Turning Point Therapeutics Inc ( NASDAQ )

Price: $75.40
Change: +0.40 (0.53%)
Volume: 1.7 M
4:00PM ET 8/12/2022

PTC Therapeutics Inc ( NASDAQ )

Price: $52.75
Change: +0.74 (1.42%)
Volume: 518.2 K
4:00PM ET 8/12/2022

ChemoCentryx Inc ( NASDAQ )

Price: $50.72
Change: +0.12 (0.24%)
Volume: 2.9 M
4:00PM ET 8/12/2022

Ultragenyx Pharmaceutical Inc ( NASDAQ )

Price: $51.57
Change: +0.32 (0.62%)
Volume: 595.8 K
4:00PM ET 8/12/2022

Amicus Therapeutics Inc ( NASDAQ )

Price: $12.32
Change: +0.26 (2.16%)
Volume: 1.9 M
4:00PM ET 8/12/2022

Read more news Recent News

Bristol Myers Squibb Extends Turning Point Tender Offer
7:24AM ET 7/19/2022 MT Newswires

Bristol Myers Squibb Company (BMY) said Tuesday that its unit Rhumba Merger Sub has extended the expiration date of its tender offer for all outstanding...

Turning Point Therapeutics to Work With University of Texas MD Anderson Cancer Center on Precision Cancer Therapies
9:39AM ET 6/24/2022 MT Newswires

Turning Point Therapeutics (TPTX) said Friday it will work with the University of Texas MD Anderson Cancer Center to expand the evaluation of two of the...

--Guggenheim Downgrades Turning Point Therapeutics to Neutral From Buy, Adjusts Price Target to $76 From $72
12:07PM ET 6/13/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

SVB Securities Downgrades Turning Point Therapeutics to Market Perform From Outperform, Adjusts Price Target to $76 From $101
8:44AM ET 6/13/2022 MT Newswires

Turning Point Therapeutics (TPTX) has an average rating of hold and price targets ranging from $72 to $76, according to analysts polled by Capital IQ. (MT...

Company Profile

Business DescriptionTurning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. View company web site for more details
Address10628 Science Center Drive
San Diego, California 92121
Number of Employees50
Recent SEC Filing08/09/2022SC TO-T/A
President, Chief Executive Officer & DirectorAthena M. Countouriotis
Vice President-Clinical OperationsMiriam Cruz
Executive VP, Chief Financial & Accounting OfficerPaolo Tombesi
Chief Scientific Officer & VP-ChemistryGavin Hirst

Company Highlights

Price Open$74.95
Previous Close$75.00
52 Week Range$23.77 - 82.20
Market Capitalization$3.8 B
Shares Outstanding50.1 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$6.90
Beta vs. S&P 500N/A
Net Profit Margin-33,959.03%
Return on Equity-37.45%

Analyst Ratings as of 06/13/2022

Consensus RecommendationConsensus Icon
Powered by Factset